2,911 Johnson & Johnson $JNJ Shares Sold by Everett Harris & Co. CA

Everett Harris & Co. CA reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.6% during the 3rd quarter, Holdings Channel.com reports. The firm owned 466,481 shares of the company’s stock after selling 2,911 shares during the period. Johnson & Johnson makes up approximately 1.5% of Everett Harris & Co. CA’s portfolio, making the stock its 14th largest position. Everett Harris & Co. CA’s holdings in Johnson & Johnson were worth $123,496,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in JNJ. ERn Financial LLC grew its position in shares of Johnson & Johnson by 10.6% in the third quarter. ERn Financial LLC now owns 919 shares of the company’s stock valued at $243,000 after purchasing an additional 88 shares during the last quarter. Crew Capital Management Ltd increased its position in Johnson & Johnson by 7.4% during the third quarter. Crew Capital Management Ltd now owns 9,957 shares of the company’s stock worth $2,636,000 after buying an additional 686 shares in the last quarter. Choreo LLC lifted its position in shares of Johnson & Johnson by 1.5% in the third quarter. Choreo LLC now owns 142,622 shares of the company’s stock valued at $37,758,000 after acquiring an additional 2,052 shares in the last quarter. Blueprint Financial Advisors LLC purchased a new stake in shares of Johnson & Johnson in the third quarter valued at $2,793,000. Finally, Livelsberger Financial Advisory purchased a new stake in Johnson & Johnson during the 3rd quarter worth about $187,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Icotyde, J&J’s oral plaque-psoriasis treatment, is reportedly gaining traction among U.S. dermatologists and being prescribed earlier in the treatment process. Strong adoption could support pharmaceutical growth and help offset declines in older products. Does Johnson & Johnson Have a New Edge in Plaque Psoriasis?
• Positive Sentiment: J&J presented 26 abstracts at TCT 2026 supporting the safety, efficacy and cost-effectiveness of its Impella heart pumps. The data may strengthen the long-term outlook for the MedTech portfolio despite recent weakness. Johnson & Johnson Presents Impella Data at TCT 2026
• Positive Sentiment: J&J continues to be highlighted as a dependable dividend stock, supported by more than five decades of annual payout increases. That income profile can provide downside support for long-term investors. Dividend Kings With 50-Plus Years of Payout Increases
• Neutral Sentiment: J&J’s recent performance has been strong, with shares reportedly up 42% over the past year, helped by progress toward resolving talc litigation and growth from newer medicines. Analysts are debating whether that advance has already priced in much of the improvement. Johnson & Johnson Is Up 42% in a Year
• Neutral Sentiment: Broker sentiment remains generally favorable, but the article questions how much weight investors should place on consensus recommendations as J&J trades near its 52-week high and at an elevated earnings multiple. Johnson & Johnson Broker Ratings
• Negative Sentiment: MedTech growth slowed in the third quarter because of international-market challenges and weakness at Abiomed. Investors may be concerned that a rebound in the fourth quarter will not fully offset the segment’s short-term disappointment. JNJ MedTech Segment Disappoints in Q3
• Negative Sentiment: Analysts see potential earnings pressure in 2027, while the market is already assigning a premium valuation after strong gains. That combination increases the risk of profit-taking if growth slows. Johnson & Johnson Strong Q3 Growth, but 2027 Could Test Earnings
• Negative Sentiment: Pomerantz announced an investigation into potential claims on behalf of J&J investors. Although such announcements do not establish wrongdoing, they add headline and litigation risk. Pomerantz Investor Investigation

Analyst Upgrades and Downgrades

JNJ has been the subject of several recent analyst reports. Royal Bank Of Canada lowered their target price on shares of Johnson & Johnson from $290.00 to $280.00 and set an “outperform” rating for the company in a research note on Wednesday, October 14th. Weiss Ratings lowered Johnson & Johnson from a “buy (b+)” rating to a “buy (b-)” rating in a research note on Friday, October 23rd. Wells Fargo & Company increased their target price on Johnson & Johnson from $275.00 to $287.00 and gave the stock an “overweight” rating in a research report on Friday, October 16th. Leerink Partners dropped their price objective on shares of Johnson & Johnson from $276.00 to $272.00 and set an “outperform” rating for the company in a research note on Wednesday, October 14th. Finally, Stifel Nicolaus set a $260.00 price objective on shares of Johnson & Johnson in a report on Wednesday, July 15th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $275.92.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Timothy Schmid sold 33,597 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the sale, the executive vice president owned 25,447 shares of the company’s stock, valued at $6,991,308.78. This trade represents a 56.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Jennifer Taubert sold 15,000 shares of Johnson & Johnson stock in a transaction on Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the sale, the executive vice president directly owned 194,451 shares in the company, valued at $51,210,615.36. This trade represents a 7.16% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 64,515 shares of company stock worth $17,271,766 in the last 90 days. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $273.39 on Friday. Johnson & Johnson has a 52-week low of $185.12 and a 52-week high of $282.02. The firm has a fifty day moving average of $265.74 and a 200-day moving average of $246.94. The firm has a market capitalization of $658.13 billion, a P/E ratio of 41.42, a PEG ratio of 2.70 and a beta of 0.21. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The business had revenue of $25.40 billion for the quarter, compared to analyst estimates of $25.38 billion. During the same quarter in the previous year, the business posted $2.80 EPS. The business’s quarterly revenue was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, analysts predict that Johnson & Johnson will post 11.12 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be issued a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a yield of 2.0%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio is currently 81.21%.

About Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.